CONNECT1905: Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Research Institute at Nationwide Children's Hospital
Start Date
August 28, 2024
End Date
June 30, 2029
Administered By
Duke Cancer Institute
Awarded By
Research Institute at Nationwide Children's Hospital
Start Date
August 28, 2024
End Date
June 30, 2029